Alnylam Pharmaceuticals
10 open jobsGeneral information
Alnylam is an RNAi therapeutics company. It makes medicines that silence the genes that cause or contribute to disease, for patients with rare genetic conditions. Patisiran, sold as Onpattro, treats amyloidosis. Vutrisiran treats hereditary ATTR amyloidosis. The company also treats Acute Hepatic Porphyria and Primary Hyperoxaluria. It is based in Cambridge, Massachusetts.
Alnylam was founded in 2002 in Cambridge by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl and Phillip Zamore, with John Maraganore as founding CEO. In 2018, Patisiran became the first RNAi drug approved by the FDA. As of 2025 the company has 2,500 employees and made $3.71 billion in revenue.
Currently, there's a total of 10 job openings at Alnylam Pharmaceuticals. Over the last 30 days, 10 jobs were added and 0 were removed. Alnylam Pharmaceuticals is an H-1B sponsor.1
Week by week at Alnylam Pharmaceuticals
New listings added per week
Chart withheld
insufficient history
Not enough history yet
Tracking since August 14, 2026 · day 7 of 60
Velocity stats appear after 60 days of clean history. We're on day 7, with 53 days to go.
A weekly-adds chart drawn from that window would mostly show the day we started looking, not how Alnylam Pharmaceuticals hires. Every window control above is disabled, and each one says when it opens.
Roles added per week
Not yet available
suppressed until 60 days of clean history
Busiest week in this window
Not yet available
suppressed with the chart
Tracked by InterviewOS since
August 2026
Days of clean history
7 / 60
velocity stats unlock at 60 days
Open roles right now
10
Open jobs
10 open · updated todayPage 1 of 1, most recently added first · Download (CSV)2
Want to know which of these 10 jobs are worth your time? Upload your CV and we'll score how well you match each one before you apply. It's free.
Score your CV for free before you applyVisa sponsorship
Does Alnylam Pharmaceuticals sponsor visas? Using USCIS data, we've collected the number of H-1Bs granted from 2021 to 2023. Alnylam Pharmaceuticals is a likely employer for applicants who require sponsorship.3
Visa petitions approved each year (USCIS)3
| Fiscal year | Approved |
|---|---|
| FY2021 | 27 |
| FY2022 | 0 |
| FY2023 | 0 |
Based on public USCIS and Department of Labor records. Past filings do not guarantee future sponsorship. Browse all H1B sponsors →
Similar companies
Common questions
Is Alnylam Pharmaceuticals hiring now?
Our last read of their board held 10 open jobs. The newest was posted February 20, 2026.
Does Alnylam Pharmaceuticals sponsor H-1B visas?
Yes. Government records show 27 approved petitions from FY2021 to FY2023.
Interview OS
Company pages built from daily checks of real hiring systems.
Notes & sources
- 1. Company description. Written by InterviewOS from Alnylam Pharmaceuticals's public materials and press coverage; facts are checked against the sources below.
- 2. Live counts. Deduplicated live listings observed daily on Alnylam Pharmaceuticals's own hiring system; last check September 12, 2026. Stale and syndicated posts on aggregator sites are not counted.
- 3. Federal visa records. USCIS H1B Employer Data Hub and US Department of Labor LCA disclosure files, matched to this company by name.
Sources
alnylam.com, checked daily
USCIS H-1B Employer Data Hub
US Department of Labor LCA disclosure files
About the data
Report a data issue with this page